Acalabrutinib for Waldenström Macroglobulinemia
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and activity of acalabrutinib in treating subjects with WM.
Will I have to stop taking my current medications?
The trial does not specify if you must stop all current medications, but you cannot take certain medications like immunotherapy within 4 weeks of starting, or anticoagulants like warfarin within 28 days of starting. You also cannot use proton-pump inhibitors during the trial.
How is the drug Acalabrutinib different from other treatments for Waldenström Macroglobulinemia?
Acalabrutinib is a newer, more selective Bruton tyrosine kinase (BTK) inhibitor compared to older treatments like ibrutinib, which means it targets the cancer cells more precisely and may have fewer side effects. It is used as a monotherapy, meaning it is given alone without combining with other drugs, which can reduce the risk of toxic effects seen with traditional chemoimmunotherapy.12345
Who Is on the Research Team?
AstraZeneca Clinical study Information Center
Principal Investigator
1-877-240-9479 information.center@astrazeneca.com
Are You a Good Fit for This Trial?
This trial is for adults with Waldenström Macroglobulinemia (WM), a type of blood cancer. It's open to those who haven't been treated before and want an alternative to chemoimmunotherapy, as well as patients whose WM has returned or didn't respond to at least one prior treatment. Participants must be able to swallow capsules and agree to use effective contraception if applicable.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive acalabrutinib to evaluate safety, pharmacokinetics, pharmacodynamics, and activity in treating Waldenström Macroglobulinemia
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Acalabrutinib (ACP-196)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Acerta Pharma BV
Lead Sponsor